In Brief: Novopharm
This article was originally published in The Tan Sheet
Executive Summary
Novopharm: Plans to launch nicotine gums for smoking cessation under an exclusive license with Premedent Technologies, a San Diego-based company specializing in chewing gum delivery systems. Pharmaceutical companies have expressed interest in a generic version of SmithKline Beecham's Nicorette as well as branded nicotine gums, and chain drug stores have inquired about store brand and private label versions, Toronto-based Novopharm notes. The firm plans to file an application with FDA for the nicotine gum in the third quarter and anticipates approval next year; Nicorette Waxman/Hatch exclusivity expires Feb. 9, 1999. Novopharm expects "revenues of about $100 mil. in the first year of launch from both licensing fees and a steady stream of royalties for nicotine gum alone." Other products in development include gums to administer medications to cancer patients, OTCs, and herbal and vitamin formulations...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning